Sartorius Stedim Biotech S.A.
SRTOY · OTC
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 3.49B | 1.82B | 1.08B | 876.10M | 0.95 |
| 2023 FY | 2.78B | 1.23B | 484.50M | 309.70M | 0.34 |
| 2024 FY | 2.78B | 1.21B | 370.60M | 175.10M | 0.18 |
| 2025 FY | 2.85B | 1.29B | 527.33M | 255.12M | 0.03 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 5.07B | 2.55B | 107.10M | 1.14B | 2.45B |
| 2023 FY | 7.74B | 5.07B | 116.60M | 3.68B | 2.64B |
| 2024 FY | 8.26B | 4.23B | 678.90M | 2.87B | 3.99B |
| 2025 FY | 8.01B | 3.89B | 425.92M | 2.60B | 4.09B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 612.30M | -430.60M | 181.70M | -116.10M | -116.50M |
| 2023 FY | 746.40M | -473.60M | 272.80M | -132.70M | 9.50M |
| 2024 FY | 815.10M | -339.80M | 475.30M | -67.10M | 562.30M |
| 2025 FY | 517.34M | -377.68M | 139.66M | -64.45M | -172.41M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 26.68B | 27.71B | — | — | — |
| 2023 FY | 22.87B | 26.44B | — | — | — |
| 2024 FY | 18.36B | 20.56B | — | — | — |
| 2025 FY | 196.82B | 199.00B | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 745.00M | 344.70M | 129.00M | 68.50M | 0.07 |
| 2025 Q3 | 704.07M | 326.65M | 139.38M | 64.05M | 0.01 |
| 2025 Q4 | 764.96M | 264.56M | 113.92M | 36.97M | 0.00 |
| 2026 Q1 | 774.02M | 351.08M | 145.96M | 89.55M | 0.01 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 8.31B | 4.27B | 699.30M | 2.97B | 4.00B |
| 2025 Q3 | 7.91B | 3.82B | 299.66M | 2.57B | 4.05B |
| 2025 Q4 | 8.01B | 3.89B | 425.92M | 2.75B | 4.09B |
| 2026 Q1 | 8.20B | 4.05B | 521.74M | 2.62B | 4.11B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | 124.90M | -75.90M | 49.00M | -67.10M | -8.30M |
| 2025 Q3 | 66.06M | -135.00M | -68.42M | -2.00M | -401.00M |
| 2025 Q4 | 235.45M | -114.34M | 121.11M | -347.29K | 127.21M |
| 2026 Q1 | 185.60M | -70.74M | 114.86M | — | 86.96M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 20.37B | 22.64B | — | — | — |
| 2025 Q3 | 182.71B | 184.98B | — | — | — |
| 2025 Q4 | 195.12B | 197.44B | — | — | — |
| 2026 Q1 | 162.11B | 164.21B | — | — | — |